As of today (2024-06-09), the Forward Annual Dividend Yield of Marizyme is 0.00%.
As of today (2024-06-09), the Trailing Annual Dividend Yield of Marizyme is 0.00%.
MRZM's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.68 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Marizyme's Forward Dividend Yield %
For the Biotechnology subindustry, Marizyme's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marizyme's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marizyme's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Marizyme's Forward Dividend Yield % falls into.
Marizyme Forward Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Thank you for viewing the detailed overview of Marizyme's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRZM has been successfully added to your